Phase 2
Completed N=26
Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation
Acute Wounds
Source: ClinicalTrials.gov NCT00816101 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Mar 2011
Primary outcomePrimary: Number of Patients Who Experienced 50% or Greater Wound Healing — 13; 7; 4 Participants
Summary
The purpose of this pilot clinical study is to compare healing rates, pain levels, and incidence of wound complications including infection with the use of a moist PROCELLERA™ Antimicrobial Wound Dressing when compared to a standard dressing, Mepilex® Border Lite, following curettage and electrodesiccation of skin lesions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Who Experienced 50% or Greater Wound Healing |
13; 7; 4 | — |
| SECONDARY Number of Patients Reporting Pain |
0; 0; 0 | — |
| SECONDARY Erythema at Week 3 |
0.45; 1.29; 0.60 | — |
Eligibility Criteria
Inclusion Criteria
If female, must either be not of childbearing potential or if they are of childbearing potential must have a negative urine pregnancy test.
- Wound size greater than 1x1 cm
- Wounds must be ≥5 cm away from all other wounds
- Wound size must not be diminished in size greater than 10% between enrollment in study and the prescreening
- Participant agrees to participate in follow-up evaluation
- Participant must be able to read and understand informed consent, and sign the informed consent
Exclusion Criteria
- Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study
- Participant is to receive another topical antimicrobial agent other than the study dressing
- Participant with sensitivity or adverse reactions to silver or zinc
- Pregnancy or nursing an infant or child
- Immunosuppression
- Active or systemic infection
- Peripheral vascular occlusive disease
- Collagen vascular disease
- Connective tissue disease
- Diabetes
- Venous stasis ulcers
- Participant undergoing active cancer chemotherapy
- Chronic steroid use
- Decision impairment
Data sourced from ClinicalTrials.gov (NCT00816101). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.